Overview

CRF2 Agonist for the Treatment of Worsening Heart Failure

Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
Phase:
PHASE2
Details
Lead Sponsor:
Corteria Pharmaceuticals
Collaborator:
Worldwide Clinical Trials